Key Therapeutic Areas for Biomarker Services
Nexelis has assessed renal toxicity (AKI) for over 40 drug programs since 2010. Our FDA-qualified tubular injury safety biomarker panel was approved for Phase I trials to aid in the detection of kidney tubular injury. This new gold standard includes six urinary biomarkers: Clusterin (CLU), Cystatin-C (CysC), Kidney Injury Molecule-1 (KIM-1), N-acetyl-beta-D-glucosaminidase (NAG), Neutrophil Gelatinase-Associated Lipocalin (NGAL), and Osteopontin (OPN).
Global preclinical and clinical exploratory solutions, decades of experience, and multiplatform approaches improve decision-making in your oncology development program. Rely on our comprehensive portfolio of biomarker assays for cytokines, chemokines, inflammatory markers, cellular pathway targets, and immuno-oncology multiplex panels.
Metabolism and Inflammation
We participated in more than 35 studies (Phase I-III) in the last four years with a NASH or related indication (primary biliary cirrhosis, chronic hepatitis B, alcoholic hepatitis, hepatobiliary disorders). Among other areas, our expertise includes:
- NAFLD/NASH and other dyslipidemias
- Insulin Resistance and Type 2 Diabetes Mellitus (T2DM)
- Gut hormones
From recent acquisitions to our award-winning work on SARS-CoV-2, Nexelis continues our long-standing dedication in developing biomarker assays for measuring inflammatory response in various infectious diseases and vaccines. We continue to invest in our laboratories and expand our biomarker portfolio for infectious diseases.